Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-19
2010-06-22
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S283700, C546S284100
Reexamination Certificate
active
07741345
ABSTRACT:
The invention is related to compounds of Formula I:or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
REFERENCES:
patent: 4816570 (1989-03-01), Farquhar
patent: 4968788 (1990-11-01), Farquhar
patent: 5461067 (1995-10-01), Norbeck et al.
patent: 5663159 (1997-09-01), Starrett, Jr. et al.
patent: 5792756 (1998-08-01), Starrett, Jr. et al.
patent: 5912352 (1999-06-01), Fassler et al.
patent: 2004/0100960 (2004-05-01), Mehta
patent: 2005/0159469 (2005-07-01), Randolph et al.
patent: WO-2005/061487 (2005-07-01), None
patent: WO-2005064008 (2005-07-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Bold, G.-et al. (1998) “New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors: Candidates for Clinical Development”J. Med. Chem.41:3387-3401.
Ermolieff, J. et al. (1997) “Kinetic Properties of Saquinavir-Resistant Mutants of HIV Type 1 Protease and their Implications in Drug Resistance in Vivo”Biochemistry36:12364-12370.
Farquhar, D. et al. (1983) “Biologically Reversible Phosphate-Protective Groups”J. Pharm. Sci.72(3):324-325.
Miller, J. (2004) “Novel arylsuflonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains” Bioorg. Med. Chem. Ltr. 14:959-963.
Toth, M. et al (1990) “A simple, continuous fluorometic assay for HIV protease”Int. J. Peptide Protein Res.36:544-550.
Weislow, O., et al. (1989) “New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity”J. of the Nat'l. Cancer Inst.81(8) 577-586.
Cannizzaro Carina E.
Chen James M.
Desai Manoj C.
Mitchell Michael L.
Swaminathan Sundaramoorthi
Gilead Sciences, Inc.
Saeed Kamal A
Shterengarts Samantha L
Zhang Cynthia H.
LandOfFree
AZA-peptide protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with AZA-peptide protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and AZA-peptide protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4209519